Nervous System Diseases
Conditions
Interventions
Aspirin Arm
Cilostazol Arm
Sponsors
Hany Aref
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patient aged 45 or Above suffering from incidental cerebral SVD Patients presenting with slowly progressive cognitive, urinary, gait abnormalities and/or depression, rather than acute stroke presentation. MRI brain suggestive of small vessel disease in the form of deep white matter hyperintensities (WMH), lacunes, cerebral microbleeds, enlarged Virchow spaces, silent small subcortical infarct
Exclusion criteria
Exclusion criteria: ? Patients with acute onset stroke of any source (Ex: CADASIL) ? Patients with past history of acute large vessel stroke ? Patients with large vessel occlusion or stenosis >50% ? Contraindication to MRI (as pacemakers or metal plates and screws) ? Alcohol addiction or substance abuse (to exclude substance induced vasculitis) ? Any neurological disease affecting white matter (eg; Multiple sclerosis, sarcoidosis, etc), ? Any neurological disease presenting with symptoms similar to cerebral small vessel disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Describe Progression of lesions in MRI after one year of receiving single antiplatlet;Explore the progression of the white matter intensities, lacunes, microbleeds and brain atrophy in the studied groups.;Assess the difference in cognitive performance, gait and sphincteric affection in SVD patients between the intervention groups (aspirin versus cilostazol). | — |
Secondary
| Measure | Time frame |
|---|---|
| Assess side effects of aspirin versus ciolstazol in patients with incidental cerebral small vessel disease | — |
Countries
Egypt
Contacts
Public ContactYasmine Abdelhamid
Assistant lecturer of neurology Ain Shams University
Outcome results
None listed